Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
Brugts JJ, Boersma E, Chonchol M, Deckers JW, Bertrand M, Remme WJ, Ferrari R, Fox K, Simoons ML; EUROPA Investigators. Brugts JJ, et al. Among authors: remme wj. J Am Coll Cardiol. 2007 Nov 27;50(22):2148-55. doi: 10.1016/j.jacc.2007.08.029. Epub 2007 Nov 13. J Am Coll Cardiol. 2007. PMID: 18036453 Free article. Clinical Trial.
Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPA.
van der Leeuw J, Oemrawsingh RM, van der Graaf Y, Brugts JJ, Deckers JW, Bertrand M, Fox K, Ferrari R, Remme WJ, Simoons ML, Boersma E, Visseren FL. van der Leeuw J, et al. Among authors: remme wj. Int J Cardiol. 2015 Mar 1;182:194-9. doi: 10.1016/j.ijcard.2014.12.046. Epub 2014 Dec 23. Int J Cardiol. 2015. PMID: 25577762 Free article. Clinical Trial.
Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.
Bertrand ME, Ferrari R, Remme WJ, Simoons ML, Fox KM. Bertrand ME, et al. Among authors: remme wj. Am Heart J. 2015 Dec;170(6):1092-8. doi: 10.1016/j.ahj.2015.08.018. Epub 2015 Aug 28. Am Heart J. 2015. PMID: 26678630 Clinical Trial.
Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.
Oemrawsingh RM, Akkerhuis KM, Van Vark LC, Redekop WK, Rudez G, Remme WJ, Bertrand ME, Fox KM, Ferrari R, Danser AH, de Maat M, Simoons ML, Brugts JJ, Boersma E; PERGENE investigators. Oemrawsingh RM, et al. Among authors: remme wj. J Am Heart Assoc. 2016 Mar 28;5(3):e002688. doi: 10.1161/JAHA.115.002688. J Am Heart Assoc. 2016. PMID: 27021566 Free PMC article. Clinical Trial.
Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.
Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlöf B, Deanfield J, Diez J, Drexler H, Ferrari R, Van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Lüscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M. Dzau VJ, et al. Cardiovasc Drugs Ther. 2002 Mar;16(2):149-60. doi: 10.1023/a:1015709617405. Cardiovasc Drugs Ther. 2002. PMID: 12090908 Review.
Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study).
Rodriguez-Granillo GA, Vos J, Bruining N, Garcia-Garcia HM, de Winter S, Ligthart JM, Deckers JW, Bertrand M, Simoons ML, Ferrari R, Fox KM, Remme W, De Feyter PJ; Investigators of the EUROPA Study. Rodriguez-Granillo GA, et al. Am J Cardiol. 2007 Jul 15;100(2):159-63. doi: 10.1016/j.amjcard.2007.02.073. Epub 2007 May 30. Am J Cardiol. 2007. PMID: 17631061 Clinical Trial.
207 results